These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11081814)

  • 41. Disease modifying treatment in multiple sclerosis.
    Fuller GN; Bone I
    J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract]   [Full Text] [Related]  

  • 42. Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate.
    Krečak I; Celić-Bunikić S; Skelin M; Lucijanić M; Verstovsek S; Kušec R
    Ann Hematol; 2022 Aug; 101(8):1885-1886. PubMed ID: 35461396
    [No Abstract]   [Full Text] [Related]  

  • 43. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes.
    Wiendl H; Hohlfeld R
    Neurology; 2009 Mar; 72(11):1008-15. PubMed ID: 19289741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
    Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
    Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.
    Flechter S; Kott E; Steiner-Birmanns B; Nisipeanu P; Korczyn AD
    Clin Neuropharmacol; 2002; 25(1):11-5. PubMed ID: 11852290
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Rare and clinically relevant adverse reactions following subcutaneous administration of glatiramer acetate].
    Sevilla Ortiz M; Martínez Martínez L; Piñeiro Corrales G
    Farm Hosp; 2011; 35(3):160-1. PubMed ID: 21441052
    [No Abstract]   [Full Text] [Related]  

  • 47. Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate.
    Jolly H; Simpson K; Bishop B; Hunter H; Newell C; Denney D; Oleen-Burkey M
    J Neurosci Nurs; 2008 Aug; 40(4):232-9. PubMed ID: 18727339
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 49. Evidence for use of glatiramer acetate in multiple sclerosis.
    Caramanos Z; Arnold DL
    Lancet Neurol; 2005 Feb; 4(2):74-5; discussion 76-7. PubMed ID: 15664538
    [No Abstract]   [Full Text] [Related]  

  • 50. Evidence for use of glatiramer acetate in multiple sclerosis.
    Comi G; Hartung HP; Martinelli Boneschi F
    Lancet Neurol; 2005 Feb; 4(2):75-6; discussion 76-7. PubMed ID: 15664539
    [No Abstract]   [Full Text] [Related]  

  • 51. Glatiramer acetate during early pregnancy: A prospective cohort study.
    Herbstritt S; Langer-Gould A; Rockhoff M; Haghikia A; Queisser-Wahrendorf A; Gold R; Hellwig K
    Mult Scler; 2016 May; 22(6):810-6. PubMed ID: 26754804
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe anaphylactic reaction to glatiramer acetate with specific IgE.
    Rauschka H; Farina C; Sator P; Gudek S; Breier F; Schmidbauer M
    Neurology; 2005 Apr; 64(8):1481-2. PubMed ID: 15851756
    [No Abstract]   [Full Text] [Related]  

  • 53. [Multiple sclerosis and pregnancy].
    Ruuskanen J; Malm H; Airas L
    Duodecim; 2013; 129(14):1457-64. PubMed ID: 23961604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".
    Filippi M; Rovaris M; Rocca MA; Sormani MP; Wolinsky JS; Comi G;
    Neurology; 2001 Aug; 57(4):731-3. PubMed ID: 11524494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Confusion over UK beta-interferon "trials".
    Dean M
    Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
    [No Abstract]   [Full Text] [Related]  

  • 56. Successful Rapid Desensitization to Glatiramer Acetate in a Patient With Multiple Sclerosis.
    Syrigou E; Psarros P; Grapsa D; Syrigos K
    J Investig Allergol Clin Immunol; 2015; 25(3):214-5. PubMed ID: 26182688
    [No Abstract]   [Full Text] [Related]  

  • 57. [Disease modifying therapies in multiple sclerosis].
    Fukaura H
    Nihon Rinsho; 2014 Nov; 72(11):2015-22. PubMed ID: 25518387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis.
    Duda PW; Schmied MC; Cook SL; Krieger JI; Hafler DA
    J Clin Invest; 2000 Apr; 105(7):967-76. PubMed ID: 10749576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study.
    Soares Almeida LM; Requena L; Kutzner H; Angulo J; de Sa J; Pignatelli J
    J Am Acad Dermatol; 2006 Dec; 55(6):968-74. PubMed ID: 17097393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.